Top
Exogenous maltose enhances Zebrafish immunity to levofloxacin‐resistant Vibrio alginolyticus
Exogenous maltose enhances Zebrafish immunity to levofloxacin‐resistant Vibrio alginolyticus
DOI: 10.1111/1751-7915.13582, Volume: 13, Issue: 4, Pages: 1213-1227
Article Type: research-article,
Article History
received:
rev-recd:
accepted:
published:
-
-
-
- Altmetric
https://www.researchpad.co/tools/openurl?pubtype=&doi=10.1111/1751-7915.13582&title=Exogenous maltose enhances Zebrafish immunity to levofloxacin‐resistant <i>Vibrio alginolyticus</i>
&author=&keyword=[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],[{keywordId=134, uniqueName=type-2-diabetes, name=Type 2 diabetes, contentId=22057}, {keywordId=14833, uniqueName=utility, name=utility, contentId=22057}, {keywordId=39592, uniqueName=(4–6):-health-state-utility, name=(4–6): Health state utility, contentId=22057}, {keywordId=39593, uniqueName=treatment-process-utility, name=Treatment process utility, contentId=22057}, {keywordId=39594, uniqueName=route-of-administration, name=Route of administration, contentId=22057}, {keywordId=39595, uniqueName=glucagon-like-peptide-1-receptor-agonist, name=Glucagon-like peptide-1 receptor agonist, contentId=22057}, {keywordId=39596, uniqueName=glp-1-ra, last=true, name=GLP-1 RA, contentId=22057}],&subject=
© 2024 Newgen KnowledgeWorks |
Privacy & Cookie Policy | Powered by: Nova